Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Awaits Data On Clinical Significance Of Vimizim Neutralizing Antibodies

19 Nov 2014

• By Derrick Gingery

Related Content

BioMarin’s Vimizim Secures Broad Label In Morquio A Syndrome

18 Feb 2014

Continued Genzyme Problems Offer Gaucher Opportunity To Competitors

07 Sep 2009

<em>Bydureon</em> Approval Provides Lesson In Clinical Data Requirements For Biosimilars

01 Jul 2012

<em>Vimizim</em> Panel’s Desire For Quality-Of-Life Data Runs Into Regulatory Reality

25 Nov 2013

Related Companies

BioMarin Pharmaceutical Inc.

Sanofi Genzyme

Additional Topics

United States Clinical Trials Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.